Belantamab Mafodotin Monotherapy for Multiply‐Relapsed Myeloma: A Retrospective Study From the United Kingdom and the Republic of Ireland

Belantamab Mafodotin Monotherapy for Multiply‐Relapsed Myeloma: A Retrospective Study From the United Kingdom and the Republic of Ireland

ABSTRACT Introduction Belantamab mafodotin (belamaf) was the first BCMA‐targeting immunotherapy licensed in myeloma and was available as monotherapy for a fifth or greater line of treatment. Outcomes for patients in the United Kingdom and the Republic of Ireland potentially differ from those of othe...

Full description

Saved in:
Bibliographic Details
Main Authors: Edmund C. R. Watson, Faouzi Djebbari, Fotios Panitsas, Grant Vallance, Samir Asher, Malahat Saeed, Mairi Walker, Matthew Powell, Alexandros Rampotas, Heather Leary, Akhil Khera, Angharad Atkinson, Ni Ni Aung, Gillian Brearton, Joseph Froggatt, Ezzat El Hassadi, Ellen Gokkel, Sarah Lawless, Beena Salhan, Salim Shafeek, Anand Lokare, Carol Stirling, Udo Oppermann, Richard Soutar, Rakesh Popat, Charalampia Kyriakou, Karthik Ramasamy
Format: Article
Language:English
Published: Wiley 2025-06-01
Series:eJHaem
Subjects:
BCMA
belantamab mafodotin
immunotherapy
keratopathy
real‐world
Online Access:https://doi.org/10.1002/jha2.70039
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://doi.org/10.1002/jha2.70039

Similar Items